Plasma asymmetric dimethylarginine is associated with vulnerable plaque and long-term outcomes in stable coronary artery disease
Abstract Asymmetric dimethylarginine (ADMA) is considered to be an atherogenic molecule. We aimed to investigate the relationship between ADMA and plaque vulnerability assessed by optical coherence tomography (OCT) in patients with stable coronary artery disease (CAD). Two hundred and forty-five pat...
Main Authors: | Shao-Sung Huang, Wei-Chieh Huang, Chuan-Tsai Tsai, Ying-Ying Chen, Sheng-Hua Lee, Tse-Min Lu |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2023-05-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-023-32728-9 |
Similar Items
-
Plasma asymmetric dimethylarginine and adverse events in patients with atrial fibrillation referred for coronary angiogram.
by: Tze-Fan Chao, et al.
Published: (2013-01-01) -
The levels of asymmetric dimethylarginine in patients with isolated coronary artery ectasia
by: Erden Ismail
Published: (2010-01-01) -
Toxic Dimethylarginines: Asymmetric Dimethylarginine (ADMA) and Symmetric Dimethylarginine (SDMA)
by: You‐Lin Tain, et al.
Published: (2017-03-01) -
Renal asymmetric dimethylarginine inhibits fibrosis
by: Ming Wu, et al.
Published: (2020-10-01) -
Asymmetric Dimethylarginine: Clinical Applications in Pediatric Medicine
by: You-Lin Tain, et al.
Published: (2011-02-01)